X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with ASTRAZENECA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ASTRAZENECA PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA ASTRAZENECA PHARMA ABBOTT INDIA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 43.9 104.7 41.9% View Chart
P/BV x 11.0 14.9 73.5% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
ASTRAZENECA PHARMA
Mar-14
ABBOTT INDIA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,0151,285 468.1%   
Low Rs3,707634 584.7%   
Sales per share (Unadj.) Rs1,236.9189.6 652.4%  
Earnings per share (Unadj.) Rs122.2-0.2 -60,009.2%  
Cash flow per share (Unadj.) Rs129.03.8 3,354.9%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.268.6 759.4%  
Shares outstanding (eoy) m21.2525.00 85.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.95.1 77.7%   
Avg P/E ratio x39.8-4,712.7 -0.8%  
P/CF ratio (eoy) x37.7249.6 15.1%  
Price / Book Value ratio x9.314.0 66.7%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,29623,988 430.6%   
No. of employees `0003.01.6 189.6%   
Total wages/salary Rs m3,3701,605 210.0%   
Avg. sales/employee Rs Th8,891.83,040.2 292.5%   
Avg. wages/employee Rs Th1,140.01,029.2 110.8%   
Avg. net profit/employee Rs Th878.3-3.3 -26,901.6%   
INCOME DATA
Net Sales Rs m26,2844,740 554.6%  
Other income Rs m50492 547.7%   
Total revenues Rs m26,7894,832 554.4%   
Gross profit Rs m3,665-130 -2,823.9%  
Depreciation Rs m144101 142.7%   
Interest Rs m80-   
Profit before tax Rs m4,017-139 -2,892.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,4215 27,917.5%   
Profit after tax Rs m2,596-5 -51,007.9%  
Gross profit margin %13.9-2.7 -509.2%  
Effective tax rate %35.4-3.7 -965.3%   
Net profit margin %9.9-0.1 -9,198.0%  
BALANCE SHEET DATA
Current assets Rs m14,4462,726 529.9%   
Current liabilities Rs m4,7252,435 194.0%   
Net working cap to sales %37.06.1 601.6%  
Current ratio x3.11.1 273.1%  
Inventory Days Days5174 69.7%  
Debtors Days Days2041 48.0%  
Net fixed assets Rs m1,1131,035 107.5%   
Share capital Rs m21350 425.0%   
"Free" reserves Rs m10,808942 1,146.8%   
Net worth Rs m11,0761,716 645.5%   
Long term debt Rs m00-   
Total assets Rs m16,2414,156 390.8%  
Interest coverage x497.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.61.1 141.9%   
Return on assets %16.0-0.1 -13,093.6%  
Return on equity %23.4-0.3 -7,902.3%  
Return on capital %36.30-  
Exports to sales %0.65.7 10.8%   
Imports to sales %12.66.5 195.6%   
Exports (fob) Rs m162270 59.8%   
Imports (cif) Rs m3,322306 1,084.7%   
Fx inflow Rs m268375 71.5%   
Fx outflow Rs m3,927470 835.4%   
Net fx Rs m-3,659-96 3,829.8%   
CASH FLOW
From Operations Rs m2,514-8 -31,040.7%  
From Investments Rs m-800-146 548.7%  
From Financial Activity Rs m-803862 -93.1%  
Net Cashflow Rs m912709 128.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 7.9 0.3 2,633.3%  
FIIs % 0.1 15.7 0.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 9.1 187.9%  
Shareholders   18,270 12,856 142.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 21, 2018 01:07 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS